Coventry, United Kingdom, 10th March 2022 / NanoSyrinx, a biotech company using synthetic biology approaches to develop a new modality for the targeted intracellular delivery of biologic therapeutics, has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer.
News
Huge demand for commercial lab and office space at Newcastle’s Biosphere means private sector investment is now being sought to take the lead on expanding the heart of the north east’s £1.7bn life science eco-system.
Located at Newcastle Helix, The Biosphere launched in 2019 as a publicly funded project, led by Newcastle City Council; it represented a significant investment for the local economy and showed a clear commitment to life sciences growth.
Cambridge, UK, 7th March 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.
Cambridge, United Kingdom, 3rd March 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, announces that it has purchased over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The new equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.
Stevenage Bioscience Catalyst (SBC) has launched an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more quickly.
Cambridge, UK, 01 March 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board.
AMSBIO reports how researchers at the Washington University School of Medicine (St. Louis, USA) have used their 10E4 Heparan Sulfate (HS) antibody in pioneering obesity research to quantify the role of HS in the process of intercellular mitochondria transfer to macrophages.
Cambridge, UK, 28th February 2022: Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village.